• Tuesday, August 20, 2019 @ 11:00 am
  • Revenue from Cresemba and Zevtera increased by 91% to CHF 53 million
  • Operating result improved by 35%
  • Expansion of derazantinib clinical program into urothelial cancer with immunotherapy combination
  • Positive phase 3 topline results from skin infection (ABSSSI) study with ceftobiprole
  • Half-year cash position of CHF 178 million

You may also be interested in